Lisa G Horvath

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/881770/publications.pdf

Version: 2024-02-01

90 papers	5,992 citations	87888 38 h-index	85541 71 g-index
94 all docs	94 docs citations	94 times ranked	10839 citing authors

#	Article	IF	Citations
1	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	1.6	29
2	Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 2022, 14, 1708.	3.7	6
3	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 2022, 20, 112.	5.5	6
4	GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.7	0
5	Mainstream consent programs for genetic counseling in cancer patients: A systematic review. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 163-177.	1.1	29
6	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2021, 7, 63-70.	3.1	10
7	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 613-620.	2.3	0
8	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
9	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 860-870.	3.9	14
10	Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. Translational Andrology and Urology, 2021, 10, 1688-1699.	1.4	1
11	Inhibition of guanosine monophosphate synthetase (<scp>GMPS</scp>) blocks glutamine metabolism and prostate cancer growth. Journal of Pathology, 2021, 254, 135-146.	4.5	19
12	Plasma Cellâ€“Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2021, 5, 622-637.	3.0	18
13	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 2021, 13, 81.	8.2	25
14	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. Cancer Research, 2021, 81, 4981-4993.	0.9	43
15	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	1.9	28
16	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Science Advances, 2021, 7, eabh0363.	10.3	23
17	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 2021, 72, 103625.	6.1	23
18	Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4964.	3.7	13

#	Article	IF	Citations
19	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. Journal of Pain, 2020, 21, 44-58.	1.4	22
20	Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. European Urology, 2020, 78, 173-180.	1.9	45
21	Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. Cancers, 2020, 12, 1385.	3.7	9
22	Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine, 2020, 54, 102728.	6.1	65
23	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.3	12
24	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. ELife, 2020, 9, .	6.0	104
25	p53 nuclear accumulation as an early indicator of lethal prostate cancer. British Journal of Cancer, 2019, 121, 578-583.	6.4	10
26	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	27.0	982
27	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia, 2019, 21, 389-400.	5.3	20
28	DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns. Cancer Cell, 2019, 35, 297-314.e8.	16.8	62
29	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15.	4.1	11
30	Exceptional Response to ¹⁷⁷Lutetium Prostate-Specific Membrane Antigen in Prostate Cancer Harboring DNA Repair Defects. JCO Precision Oncology, 2019, 3, 1-5.	3.0	10
31	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. European Urology, 2019, 76, 306-312.	1.9	26
32	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. Molecular Cancer Research, 2019, 17, 949-962.	3.4	65
33	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	5.1	13
34	Results of a Prospective Phase 2 Pilot Trial of 177Luâ€“PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clinical Genitourinary Cancer, 2019, 17, 15-22.	1.9	131
35	Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. Molecular and Cellular Proteomics, 2018, 17, 1470-1486.	3.8	26
36	Effect of FAK inhibitor VSâ€6063 (defactinib) on docetaxel efficacy in prostate cancer. Prostate, 2018, 78, 308-317.	2.3	48

#	Article	IF	Citations
37	Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. Prostate, 2018, 78, 25-31.	2.3	19
38	Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axisâ€“targeting Agents in Metastatic Castration-resistant Prostate Cancer. European Urology, 2018, 73, 818-821.	1.9	35
39	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Investigational New Drugs, 2018, 36, 886-894.	2.6	18
40	MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Scientific Reports, 2018, 8, 7820.	3.3	33
41	Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics and Chromatin, 2018, 11, 24.	3.9	38
42	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. Npj Systems Biology and Applications, 2018, 4, 20.	3.0	47
43	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
44	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
45	Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 2017, 116, 1002-1011.	6.4	48
46	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 2017, 128, 1166-1175.	1.5	50
47	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493.	2.2	59
48	Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with longâ€term followâ€up. BJU International, 2017, 120, 651-658.	2.5	30
49	Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer. Nature Communications, 2017, 8, 1346.	12.8	68
50	Screening for <scp>ROS</scp>1 gene rearrangements in nonâ€smallâ€cell lung cancers using immunohistochemistry with <scp>FISH</scp> confirmation is an effective method to identify this rare target. Histopathology, 2017, 70, 402-411.	2.9	52
51	EGFRâ€“Co-Mutated Advanced NSCLC and Response toÂEGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2017, 12, 585-590.	1.1	52
52	Discovering cancer vulnerabilities using high-throughput micro-RNA screening. Nucleic Acids Research, 2017, 45, 12657-12670.	14.5	15
53	A distinct plasma lipid signature associated with poor prognosis in castrationâ€resistant prostate cancer. International Journal of Cancer, 2017, 141, 2112-2120.	5.1	54
54	Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. Aging, 2016, 8, 2702-2712.	3.1	27

#	Article	IF	Citations
55	Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer. Prostate, 2016, 76, 1491-1500.	2.3	11
56	Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular and Cellular Proteomics, 2016, 15, 2671-2685.	3.8	29
57	CMRF-56⁺blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. OncoImmunology, 2016, 5, e1168555.	4.6	17
58	Extraprostatic extension (<scp>EPE</scp>) of prostatic carcinoma: is its proximity to the surgical margin or <scp>G</scp>leason score important?. BJU International, 2015, 116, 343-350.	2.5	9
59	INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival. Prostate, 2015, 75, 92-102.	2.3	24
60	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 2015, 89, 181-188.	2.0	253
61	Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 483-497.	4.4	41
62	FAK signaling in human cancer as a target for therapeutics. , 2015, 146, 132-149.		317
63	ERG induces taxane resistance in castration-resistant prostate cancer. Nature Communications, 2014, 5, 5548.	12.8	96
64	Expression of phosphorylated-mTOR during the development of prostate cancer. Prostate, 2014, 74, 1231-1239.	2.3	21
65	Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 190-201.	4.1	42
66	Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2014, 32, 11-11.	1.6	6
67	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. Journal of Clinical Oncology, 2014, 32, 44-44.	1.6	0
68	High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International, 2012, 109, 1794-1800.	2.5	80
69	Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology, 2011, 43, 410-419.	0.6	9
70	Low AZGP1 expression predicts for recurrence in marginâ€positive, localized prostate cancer. Prostate, 2011, 71, 1638-1645.	2.3	33
71	Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 148-159.	2.5	51
72	Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocrine-Related Cancer, 2011, 18, R103-R123.	3.1	82

#	Article	IF	Citations
73	Bone disease in prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 3-4.	1.1	0
74	Stage migration in localized prostate cancer has no effect on the postâ€radical prostatectomy Kattan nomogram. BJU International, 2010, 105, 642-647.	2.5	10
75	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	2.5	145
76	Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research, 2009, 69, 7696-7703.	0.9	94
77	Androgen regulation of multidrug resistanceâ€associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate, 2008, 68, 1421-1429.	2.3	70
78	Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2488-2497.	2.5	24
79	Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate, 2007, 67, 1081-1090.	2.3	48
80	Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy. Journal of the National Cancer Institute, 2006, 98, 1420-1424.	6.3	89
81	Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 711-716.	2.5	62
82	Lower levels of nuclear Î²â€catenin predict for a poorer prognosis in localized prostate cancer. International Journal of Cancer, 2005, 113, 415-422.	5.1	59
83	Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate, 2005, 65, 222-230.	2.3	85
84	Expression of Vascular Endothelial Growth Factor Receptor-3 by Lymphatic Endothelial Cells Is Associated with Lymph Node Metastasis in Prostate Cancer. Clinical Cancer Research, 2004, 10, 5137-5144.	7.0	102
85	Membranous Expression of Secreted Frizzled-Related Protein 4 Predicts for Good Prognosis in Localized Prostate Cancer and Inhibits PC3 Cellular Proliferation in Vitro. Clinical Cancer Research, 2004, 10, 615-625.	7.0	79
86	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate, 2004, 59, 234-242.	2.3	98
87	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene, 2003, 22, 6005-6012.	5.9	103
88	Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Research, 2003, 63, 4196-203.	0.9	185
89	Unusual Presentations of Germ Cell Tumors. Journal of Clinical Oncology, 2001, 19, 909-911.	1.6	2
90	Unusual Presentations of Germ Cell Tumors. Journal of Clinical Oncology, 2001, 19, 911-915.	1.6	15